Latest News

ACOG updated HIV screening and prevention guidance, recommending opt-out lifetime HIV testing and stronger PrEP counseling and prescribing.

A new analysis estimates the 2026 dyslipidemia guideline expands primary prevention statin eligibility to 87.5 million US adults.

FDA accepted Shionogi’s sNDA for cefiderocol for pediatric HABP/VABP and complicated UTI caused by certain Gram-negative bacteria.

The US FDA approved enlicitide (Lipfendra; Merck), the first oral PCSK9 inhibitor, to reduce LDL-C in adults with hypercholesterolemia, including HeFH.

FDA accepted Axsome’s NDA for AXS-12 for cataplexy in narcolepsy and set a PDUFA target action date of May 1, 2027.

Once-weekly subcutaneous lecanemab matched IV initiation exposure in early Alzheimer disease, but comparative clinical outcome data remain limited.

The 2026 global status report on cancer projects nearly 35 million new cases annually by 2050 and underscores urgent action on prevention and care access.

AI-generated portal message drafts often missed clinical context and required physician editing in a Dartmouth analysis.